Cyclins and related cyclin-dependent kinases play vital roles in regulating the progression in the cell cycle. Understanding the intrinsic mechanisms of cyclins promises knowledge about cell uncontrolled proliferation and prevention of cancer cells. Therefore, accurate recognition of cyclins is important for the investigation of tumor cells and biomedical engineering. This study proposes a novel sequence-based predictor named TYLER (predicT cYcLin-dEpendent pRoteins) for addressing the long challenge problem of predicting cyclin-dependent proteins (CDPs). We use information theory to compute selectively enriched CDP-related motifs and build the motif-based model. For those proteins without sharing enriched motifs, we compute sequence-derived features and construct machine learning-based models. We optimize the weights of two different models to build a more accurate predictor. We estimate these two types of models by using 5-fold cross-validations on the TRAINING dataset. We prove that the combination of two models and optimization of the corresponding weights promises decent and robust results on both TRAINING and independent TEST dataset. The empirical test demonstrates that TYLER is robust predictor and statistically significantly better than current methods. The runtime assessment reveals TYLER is a high-throughput effective method. We use TYLER to make predictions on the human proteome, and use the results to hypothesize CDPs. The latest experimental verified CDPs and GO analysis proves that some of our novel predictions shall be potential CDPs. TYLER is implemented as a public user-friendly web server at http://www.inforstation.com/webservers/TYLER/. We share all data and source code that used in this research at https://github.com/biocomputinglab/TYLER.git.

Download full-text PDF

Source
http://dx.doi.org/10.3934/mbe.2021318DOI Listing

Publication Analysis

Top Keywords

cyclin-dependent proteins
12
sequence-derived features
8
tyler
6
tyler fast
4
fast method
4
method accurately
4
accurately predicts
4
cyclin-dependent
4
predicts cyclin-dependent
4
proteins
4

Similar Publications

SPT5 regulates RNA polymerase II stability via Cullin 3-ARMC5 recognition.

Sci Adv

January 2025

Simpson Querrey Institute for Epigenetics, Department of Biochemistry and Molecular Genetics Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA.

The stability of RNA polymerase II (Pol II) is tightly regulated during transcriptional elongation for proper control of gene expression. Our recent studies revealed that promoter-proximal Pol II is destabilized via the ubiquitin E3 ligase cullin 3 (CUL3) upon loss of transcription elongation factor SPT5. Here, we investigate how CUL3 recognizes chromatin-bound Pol II as a substrate.

View Article and Find Full Text PDF

AT7519, which inhibits multiple cyclin-dependent kinases, has been extensively investigated in various types of cancer cells. Previous studies have demonstrated the ability of this molecule to suppress the expression of the nuclear receptor retinoic acid-related orphan receptor gamma (RORγ) and several genes involved in hepatocellular carcinoma progression. In this study, we identified a distinct agonistic effect of AT7519 on RORγt, an isoform expressed by various immune cells, including T helper 17 lymphocytes.

View Article and Find Full Text PDF

Introduction: The optimal treatment of estrogen receptor-positive (ER +) metastatic breast cancer (MBC) after progression on cyclin-dependent 4/6 kinase inhibitors (CDK4/6i) is unknown.

Methods: We conducted a systematic review and network meta-analysis (NMA) of phase-II/-III randomized trials of ER + MBC post CDK4/6i + ET progression. We calculated the hazard ratio (HR) for progression-free survival (PFS) and overall survival (OS) using generic inverse variance and odds ratios (ORs) using the Mantel-Haenszel method for adverse events (AEs) with Review-Manager version-5.

View Article and Find Full Text PDF

Introduction: CDK4/6 inhibitors in combination with aromatase inhibitors (AIs) are the standard first-line treatment for hormone receptor-positive (HR+), HER2-negative (HER2-) metastatic breast cancer. Landmark trials have demonstrated a comparable progression-free survival (PFS) across CDK4/6 inhibitors, but the overall survival (OS) outcomes have varied. This study aimed to evaluate the real-world PFS and OS for palbociclib and ribociclib when combined with AIs in patients with HR+/HER2- advanced breast cancer.

View Article and Find Full Text PDF

Knocking Down in Colorectal Cancer: Implications for Apoptosis and Cell Cycle Arrest via the p53 Signaling Pathway.

Discov Med

January 2025

Key Laboratory of Microecology-Immune Regulatory Network and Related Diseases, School of Basic Medicine, Jiamusi University, 154000 Jiamusi, Heilongjiang, China.

Background: Preventing the progression and recurrence of colorectal cancer (CRC) remains a clinical challenge due to its heterogeneity and drug resistance. This underscores the need to discover new targets and elucidate their cancer-promoting mechanisms. This study analyzed the cancer-promoting mechanisms of tryptophanyl-tRNA synthetase 1 () in CRC.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!